Moderna to Present Revaccination Data for Flu and RSV Vaccines

The biotech company will share late-breaking data on its mRNA-based seasonal flu and RSV vaccine candidates at an upcoming medical conference.

Apr. 7, 2026 at 12:37am

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray image showing the internal structure of a syringe filled with a glowing, luminescent liquid vaccine, conceptually representing the advanced mRNA vaccine technology being developed by Moderna.Moderna's mRNA vaccine technology aims to provide durable protection against seasonal influenza and respiratory viruses through innovative revaccination approaches.Cambridge Today

Moderna, Inc. announced that the company will present late-breaking oral presentations on revaccination data for both its investigational seasonal influenza vaccine mRNA-1010 and its mRNA-based respiratory syncytial virus (RSV) vaccine candidate mRESVIA at the 2026 European Congress of Clinical Microbiology & Infectious Diseases (ESCMID) conference.

Why it matters

Moderna's mRNA technology platform has shown promise in developing new vaccine candidates, and the company's ability to generate robust revaccination data could help support regulatory approval and widespread adoption of its seasonal flu and RSV vaccines, which target major public health challenges.

The details

The presentations will focus on the sequential administration of Moderna's mRNA-based seasonal influenza vaccine in older adults, as well as data on the company's mRNA-based RSV vaccine candidate. Successful revaccination data could demonstrate the vaccines' ability to provide durable protection, a key factor for seasonal and respiratory virus vaccines.

  • The ESCMID 2026 conference will take place from June 28-July 1, 2026.
  • Moderna plans to present the late-breaking data during the conference.

The players

Moderna, Inc.

A biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines, including investigational candidates for seasonal influenza and respiratory syncytial virus (RSV).

mRNA-1010

Moderna's investigational seasonal influenza vaccine candidate that uses the company's mRNA technology platform.

mRESVIA

Moderna's investigational mRNA-based respiratory syncytial virus (RSV) vaccine candidate.

Got photos? Submit your photos here. ›

What’s next

The presentations at ESCMID 2026 will provide important data on Moderna's progress in developing its mRNA-based seasonal flu and RSV vaccine candidates, which could support future regulatory submissions and approvals.

The takeaway

Moderna's ability to generate robust revaccination data for its mRNA-based vaccine candidates targeting major public health threats like seasonal influenza and RSV could help drive wider adoption and acceptance of these innovative vaccine technologies.